Aspirin and P2Y₁₂ Inhibitors in platelet-mediated activation of neutrophils and monocytes

Summary

Platelets are key players in haemostasis and represent a pivotal link between inflammation, immunity and atherogenesis. Depending on the (patho)physiological environment platelets modulate various leukocyte functions via release of inflammatory mediators and direct cell-cell interactions. Elevated levels of circulating platelet-leukocyte aggregates are found in patients suffering from several thrombotic or inflammatory conditions. Platelet-monocyte and platelet-neutrophil interaction can trigger pro- and anti-inflammatory responses and modulate effector functions of all leukocyte subpopulations. These platelet-mediated immune responses have implications for the progression of cardiovascular diseases and also play a crucial role during infections, cancer, transplantations and other inflammatory diseases of several organs. Antiplatelet therapy including the COX inhibitor aspirin and/or ADP receptor P2Y₁₂ inhibitors such as clopidogrel, prasugrel and ticagrelor are the therapy of choice for various cardiovascular complications. Both aspirin and P2Y₁₂ inhibitors attenuate platelet-leukocyte interactions, thereby also modulating immune responses. This may have beneficial effects in some pathological conditions, while it might be detrimental in others. This review aims to summarise the current knowledge on platelet-leukocyte interactions and the impact of aspirin and P2Y₁₂ inhibition on platelet-mediated immune responses and to give an overview on the effects of antiplatelet therapy on platelet-leukocyte interplay in various diseases.

Keywords

Platelet-leukocyte interaction - platelet immunology - inflammation - antiplatelet agents - aspirin - P2Y₁₂ inhibitors

• References

• 1 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circulation Res 2007; 100: 27-40.
• 2 Karshovska E. et al. Platelet chemokines in health and disease. Thromb Hae-most 2013; 110: 894-902.
• 3 Rondina MT. et al. Platelets as cellular effectors of inflammation in vascular diseases. Circulation Res 2013; 112: 1506-1519.
• 4 Zarbock A. et al. PSGL-1-dependent myeloid leukocyte activation. J Leukocyte Biol 2009; 86: 1119-1124.
• 5 Rinder HM. et al. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991; 78: 1730-1737.
• 6 Li N. Platelet-lymphocyte cross-talk. J Leukocyte Biol 2008; 83: 1069-1078.
• 7 van Gils JM. et al. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukocyte Biol 2009; 85: 195-204.
• 8 Schulz C. et al. EMMPRIN (CD147/basigin) mediates platelet-monocyte interactions in vivo and augments monocyte recruitment to the vascular wall. J Thromb Haemost 2011; 09: 1007-1019.
• 9 Haselmayer P. et al. TREM-1 ligand expression on platelets enhances neutrophil activation. Blood 2007; 110: 1029-1035.
• 10 Burnier L. et al. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost 2009; 101: 439-451.
• 11 Suzuki J. et al. Cytokine secretion from human monocytes potentiated by P-selectin-mediated cell adhesion. Intern Arch Allergy Immunol 2013; 160: 152-160.
• 12 Weyrich AS. et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-1534.
• 13 Lievens D. et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
• 14 Pervushina O. et al. Platelet factor 4/CXCL4 induces phagocytosis and the generation of reactive oxygen metabolites in mononuclear phagocytes independently of Gi protein activation or intracellular calcium transients. J Immunol 2004; 173: 2060-2067.
• 15 Vasina EM. et al. Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release. Am J Blood Res 2013; 03: 107-123.
• 16 Badrnya S. et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscl Thromb Vasc Biol 2014; 34: 571-580.
• 17 Phillips JH. et al. Platelet-induced expression of Fc gamma RIII (CD16) on human monocytes. Eur J Immunol 1991; 21: 895-899.
• 18 Yang J. et al. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomarker Res 2014; 02: 1.
• 19 Gorbet MB, Sefton MV. Material-induced tissue factor expression but not CD11b upregulation depends on the presence of platelets. J Biomed Mater Res Part A 2003; 67: 792-800.
• 20 Amirkhosravi A. et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemost 1996; 75: 87-95.
• 21 Kasthuri RS. et al. PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcgammaRI. Blood 2012; 119: 5285-5293.
• 22 Barnard MR. et al. Effects of platelet binding on whole blood flow cytometry as-says of monocyte and neutrophil procoagulant activity. J Thromb Haemost 2005; 03: 2563-2570.
• 23 Huo Y. et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Med 2003; 09: 61-67.
• 24 Lievens D. et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010; 116: 4317-4327.
• 25 Scheuerer B. et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
• 26 Gleissner CA. et al. CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol 2010; 184: 4810-4818.
• 27 Gleissner CA. et al. CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circulation Res 2010; 106: 203-211.
• 28 Erbel C. et al. CXCL4-induced plaque macrophages can be specifically identified by co-expression of MMP7+S100A8+ in vitro and in vivo. Innate Immun. 2014 Epub ahead of print.
• 29 Daub K. et al. Platelets induce differentiation of human CD34+ progenitor cells into foam cells and endothelial cells. FASEB J 2006; 20: 2559-2561.
• 30 Gudbrandsdottir S. et al. Activated platelets enhance IL-10 secretion and reduce TNF-alpha secretion by monocytes. J Immunol 2013; 191: 4059-4067.
• 31 Corken A. et al. Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. Arterioscl Thromb Vasc Biol 2014; 34: 996-1001.
• 32 Clark SR. et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nature Med 2007; 13: 463-469.
• 33 Zarbock A. et al. Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev 2007; 21: 99-111.
• 34 Ghasemzadeh M. et al. The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi. Blood 2013; 121: 4555-4566.
• 35 Kulkarni S. et al. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood 2007; 110: 1879-1886.
• 36 Diacovo TG. et al. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88: 146-157.
• 37 Jy W. et al. Platelet microparticles bind, activate and aggregate neutrophils in vitro. Blood Cell Mol Dis 1995; 21: 217-231.
• 38 Duerschmied D. et al. Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice. Blood 2013; 121: 1008-1015.
• 39 Rahman M. et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis. Inflam Res 2012; 61: 571-579.
• 40 Rahman M. et al. Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury. Ann Surg 2009; 250: 783-790.
• 41 Maugeri N. et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. Antiox Redox Signal 2014; 20: 1060-1074.
• 42 Lecut C. et al. ATP-gated P2X1 ion channels protect against endotoxemia by dampening neutrophil activation. J Thromb Haemost 2012; 10: 453-465.
• 43 Assinger A. et al. Efficient phagocytosis of periodontopathogens by neutrophils requires plasma factors, platelets and TLR2. J Thromb Haemost 2011; 09: 799-809.
• 44 Manfredi AA. et al. Dangerous connections: neutrophils and the phagocytic clearance of activated platelets. Curr Opin Hematol 2010; 17: 3-8.
• 45 Mantovani A. et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev Immunol 2011; 11: 519-531.
• 46 Brancaleone V. et al. A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 2013; 122: 608-617.
• 47 Diacovo TG. et al. Platelet-mediated lymphocyte delivery to high endothelial venules. Science 1996; 273: 252-255.
• 48 Elzey BD. et al. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity 2003; 19: 9-19.
• 49 Elzey BD. et al. Cooperation between platelet-derived CD154 and CD4+ T cells for enhanced germinal center formation. J Leukocyte Biol 2005; 78: 80-84.
• 50 Shi G. et al. Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest 2014; 124: 543-552.
• 51 Maitre B. et al. Immature myeloid dendritic cells capture and remove activated platelets from preformed aggregates. J Thromb Haemost 2010; 08: 2262-2272.
• 52 Langer HF. et al. Platelets recruit human dendritic cells via Mac-1/JAM-C interaction and modulate dendritic cell function in vitro. Arterioscl Thromb Vasc Biol 2007; 27: 1463-1470.
• 53 Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010; 134: 25-32.
• 54 Hagihara M. et al. Platelets, after exposure to a high shear stress, induce IL-10-producing, mature dendritic cells in vitro. J Immunol 2004; 172: 5297-5303.
• 55 Duffau P. et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Science Transl Med 2010; 02: 47ra63.
• 56 Hamzeh-Cognasse H. et al. Direct contact of platelets and their released products exert different effects on human dendritic cell maturation. BMC Immunol 2008; 09: 54.
• 57 Hilf N. et al. Human platelets express heat shock protein receptors and regulate dendritic cell maturation. Blood 2002; 99: 3676-3682.
• 58 Yusuf S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 59 Dovizio M. et al. Role of platelets in inflammation and cancer: novel therapeutic strategies. Basic Clin Pharmacol Toxicol 2014; 114: 118-127.
• 60 Murugappa S, Kunapuli SP. The role of ADP receptors in platelet function. Front Biosci 2006; 11: 1977-1986.
• 61 Santilli F. et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 2006; 47: 391-397.
• 62 Nannizzi-Alaimo L. et al. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107: 1123-1128.
• 63 Miedzobrodzki J. et al. Effect of nicotinamide and its two derivatives on the generation of reactive oxygen species in human monocytes cooperating with platelets. Acta Pol Pharm 2010; 67: 487-494.
• 64 Badrnya S. et al. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost 2012; 108: 719-729.
• 65 Li N. et al. Aspirin treatment does not attenuate platelet or leukocyte activation as monitored by whole blood flow cytometry. Thromb Res 2003; 111: 165-170.
• 66 Aktas B. et al. Aspirin induces platelet receptor shedding via ADAM17 (TACE). J Biol Chem 2005; 280: 39716-39722.
• 67 Ratnatunga CP. et al. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation. Circulation 1992; 85: 1077-1082.
• 68 Heitzer T. et al. Clopidogrel improves systemic endothelial nitric oxide bioavail-ability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol 2006; 26: 1648-1652.
• 69 Graff J. et al. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers. Clin Pharmacol Therap 2005; 78: 468-476.
• 70 Evangelista V. et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005; 94: 568-577.
• 71 Frelinger 3rd AL. et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost 2008; 06: 359-365.
• 72 Klinkhardt U. et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease. Clin Pharmacol Ther 2003; 73: 232-241.
• 73 Braun OO. et al. Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease. Thromb Haemost 2008; 100: 626-633.
• 74 Wiviott SD. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
• 75 Ortiz-Munoz G. et al. Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice. Blood 2014; 124: 2625-2634.
• 76 Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purin Signal 2012; 08: 609-619.
• 77 Diehl P. et al. Clopidogrel affects leukocyte dependent platelet aggregation by P2Y₁₂ expressing leukocytes. Basic Res Cardiol 2010; 105: 379-387.
• 78 Garcia AE. et al. Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. PloS one 2013; 08: e69093.
• 79 Harada K. et al. Adenosine diphosphate receptor P2Y₁₂-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation 2011; 92: 148-154.
• 80 Lukasik M. et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. Thromb Res 2011; 128: e73-80.
• 81 Sarafoff N. et al. Clinical use of clopidogrel. Curr Pharmaceut Des 2012; 18: 5224-5239.
• 82 Willecke F. et al. Interruption of classic CD40L-CD40 signalling but not of the novel CD40L-Mac-1 interaction limits arterial neointima formation in mice. Thromb Haemost 2014; 112: 379-389.
• 83 Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105 (Suppl. 01) S13-33.
• 84 Starlinger P. et al. Evidence for serotonin as a relevant inducer of liver regeneration after liver resection in humans. Hepatology 2014; 60: 257-266.
• 85 Laschke MW. et al. Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis. Br J Pharmacol 2008; 153: 148-156.
• 86 Zaldivar MM. et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51: 1345-1353.
• 87 Lang PA. et al. Aggravation of viral hepatitis by platelet-derived serotonin. Nature Med 2008; 14: 756-761.
• 88 Sitia G. et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109: E2165-2172.
• 89 Sitia G. et al. Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol 2013; 59: 1135-1138.
• 90 Furuichi K. et al. Chemokine/chemokine receptor-mediated inflammation regulates pathologic changes from acute kidney injury to chronic kidney disease. Clin Exp Nephrol 2009; 13: 9-14.
• 91 Peters H. et al. Platelet inhibition limits TGF-beta overexpression and matrix expansion after induction of anti-thy1 glomerulonephritis. Kidney Int 2004; 65: 2238-2248.
• 92 Zoja C, Remuzzi G. Role of platelets in progressive glomerular diseases. Ped Nephrol 1995; 09: 495-502.
• 93 Voudoukis E. et al. Multipotent role of platelets in inflammatory bowel diseases: a clinical approach. World J Gastroenterol 2014; 20: 3180-3190.
• 94 Vowinkel T. et al. CD40-CD40 ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterol 2007; 132: 955-965.
• 95 Weissmuller T. et al. PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest 2008; 118: 3682-3692.
• 96 Patel SH. et al. Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease. Indian J Pharmacol 2012; 44: 744-748.
• 97 Ananthakrishnan AN. et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study. Ann Int Med 2012; 156: 350-359.
• 98 Chan SS. et al. Aspirin in the aetiology of Crohn’s disease and ulcerative colitis: a European prospective cohort study. Aliment Pharmacol Therap 2011; 34: 649-655.
• 99 Kasperska-Zajac A. et al. Platelet function in cutaneous diseases. Platelets 2008; 19: 317-321.
• 100 Katoh N. Platelets as versatile regulators of cutaneous inflammation. J Dermatol Sci 2009; 53: 89-95.
• 101 Tamagawa-Mineoka R. et al. Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Cin Immunol 2009; 123: 581-587 e1–9.
• 102 Suzuki Y, Ra C. Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: aspirin modulation of IgE-dependent mast cell activation: role of aspirin-induced exacerbation of immediate allergy. J Pharmacol Sci 2009; 110: 237-244.
• 103 Pamuk GE. et al. Increased circulating platelet-leucocyte complexes in patients with primary Raynaud’s phenomenon and Raynaud’s phenomenon secondary to systemic sclerosis: a comparative study. Blood Coagul Fibrinol 2007; 18: 297-302.
• 104 Saleh HM. et al. Platelet activation: a link between psoriasis per se and subclinical atherosclerosis--a case-control study. Br J Dermatol 2013; 169: 68-75.
• 105 Ludwig RJ. et al. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004; 122: 830-836.
• 106 Wu S. et al. Use of Aspirin, Nonsteroidal Anti-inflammatory Drugs, and Acetaminophen (Paracetamol), and Risk of Psoriasis and Psoriatic Arthritis: A Cohort Study. Acta Derm Venereol. 2014 Epub ahead of print.
• 107 Mahajan VK. et al. Clopidogrel: a possible exacerbating factor for psoriasis. Indian J Pharmacol 2014; 46: 123-124.
• 108 Pamuk GE. et al. Elevated platelet-monocyte complexes in patients with psoriatic arthritis. Platelets 2009; 20: 493-497.
• 109 Joseph JE. et al. Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. Br J Haematol 2001; 115: 451-459.
• 110 Kirk AD. et al. Platelets influence vascularized organ transplants from start to finish. Am J Transplant 2009; 09: 14-22.
• 111 Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nature Rev Microbiol 2014; 12: 426-437.
• 112 Auerbach DJ. et al. Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. Proc Natl Acad Sci USA 2012; 109: 9569-9574.
• 113 Assinger A. et al. Human cytomegalovirus-platelet interaction triggers toll-like receptor 2-dependent proinflammatory and proangiogenic responses. Arterioscl Thromb Vasc Biol 2014; 34: 801-809.
• 114 Assinger A. Platelets and infection – an emerging role of platelets in viral infection. Front Immunol 2014; 05: 649.
• 115 O’Brien M. et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acq Immune Def Syndr 2013; 63: 280-288.
• 116 de Stoppelaar SF. et al. The role of platelets in sepsis. Thromb Haemost 2014; 112: 666-677.
• 117 Fuchs TA. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-1585.
• 118 Xiang B. et al. Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via the cyclooxygenase 1 signalling pathway. Nature Commun 2013; 04: 2657.
• 119 Weyrich AS, Zimmerman GA. Platelets in lung biology. Ann Rev Physiol 2013; 75: 569-591.
• 120 Caudrillier A, Looney MR. Platelet-neutrophil interactions as a target for prevention and treatment of transfusion-related acute lung injury. Curr Pharmaceut Des 2012; 18: 3260-3266.
• 121 Tuinman PR. et al. High-dose acetylsalicylic acid is superior to low-dose as well as to clopidogrel in preventing lipopolysaccharide-induced lung injury in mice. Shock 2013; 40: 334-338.
• 122 Laidlaw TM. et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012; 119: 3790-3798.
• 123 Nieswandt B. et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
• 124 Rothwell PM. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
• 125 Wang Y. et al. Platelet P2Y₁₂ is involved in murine pulmonary metastasis. PloS one 2013; 08: e80780.
• 126 Gebremeskel S. et al. The reversible P2Y₁₂ inhibitor ticagrelor inhibits meta-stasis and improves survival in mouse models of cancer. Int J Cancer 2015; 136: 234-240.
• 127 Roop RP. et al. A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer 2013; 13: 409-415.